| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1020811248 |
| P356 | DOI | 10.1007/S12265-013-9449-0 |
| P698 | PubMed publication ID | 23404189 |
| P50 | author | Dominick Angiolillo | Q72837721 |
| P2093 | author name string | Fabiana Rollini | |
| Francesco Franchi | |||
| Ana Muñiz-Lozano | |||
| P2860 | cites work | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q22241919 |
| Diagnosis and Classification of Diabetes Mellitus | Q22255454 | ||
| Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients | Q24555072 | ||
| Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis | Q24645413 | ||
| Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study | Q28165115 | ||
| Evaluation of anti-platelet aggregatory effects of aspirin, cilostazol and ramatroban on platelet-rich plasma and whole blood | Q28168292 | ||
| Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? | Q28168661 | ||
| Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study | Q28171078 | ||
| P2Y12 receptors play a significant role in the development of platelet microaggregation in patients with diabetes | Q28171157 | ||
| Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents | Q28174787 | ||
| Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment | Q28185431 | ||
| Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation | Q28188284 | ||
| Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood | Q28190630 | ||
| Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study | Q28190808 | ||
| Cyclooxygenase-1 haplotype modulates platelet response to aspirin | Q28191434 | ||
| Cyclooxygenase inhibitors and the antiplatelet effects of aspirin | Q28191912 | ||
| Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial | Q28193186 | ||
| Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus | Q28193753 | ||
| Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial | Q28194232 | ||
| Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events | Q28195656 | ||
| Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry | Q28195674 | ||
| Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment | Q28199546 | ||
| Platelet activation in type 2 diabetes mellitus | Q28210554 | ||
| Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation | Q28218789 | ||
| Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin | Q28219365 | ||
| Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers | Q28219399 | ||
| Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis | Q28219463 | ||
| Prevention by NCX 4016, a nitric oxide-donating aspirin, but not by aspirin, of the acute endothelial dysfunction induced by exercise in patients with intermittent claudication | Q28219820 | ||
| The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study | Q28221353 | ||
| Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives | Q28222158 | ||
| Effects of pioglitazone on platelet P2Y12-mediated signalling in clopidogrel-treated patients with type 2 diabetes mellitus | Q84561624 | ||
| The dual thromboxane receptor antagonist and thromboxane synthase inhibitor EV-077 is a more potent inhibitor of platelet function than aspirin | Q84581656 | ||
| Bedside monitoring to adjust antiplatelet therapy for coronary stenting | Q85345517 | ||
| Insulin/IGF-1 hybrid receptor expression on human platelets: consequences for the effect of insulin on platelet function | Q43264426 | ||
| Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus | Q43541597 | ||
| Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. | Q43554882 | ||
| Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium | Q43566887 | ||
| Platelet antioxidant enzymes in insulin-dependent diabetes mellitus | Q43641231 | ||
| Effects of cangrelor in coronary artery disease patients with and without diabetes mellitus: an in vitro pharmacodynamic investigation. | Q43744458 | ||
| Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes | Q43815690 | ||
| Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity | Q43852839 | ||
| Glycated low density lipoproteins modify platelet properties: a compositional and functional study | Q43982457 | ||
| Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocar | Q44056270 | ||
| Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease | Q44253003 | ||
| Enhancing effect of advanced glycation end products on serotonin-induced platelet aggregation in patients with diabetes mellitus | Q44301386 | ||
| Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity | Q44642265 | ||
| Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus | Q44668369 | ||
| Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes | Q44754180 | ||
| Improved metabolic control decreases platelet activation markers in patients with type-2 diabetes | Q44802298 | ||
| Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease | Q44938343 | ||
| Thromboxane biosynthesis and platelet function in type II diabetes mellitus | Q45056796 | ||
| Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Pati | Q46073177 | ||
| Intensive versus conventional glucose control in critically ill patients | Q46076336 | ||
| Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial | Q46105774 | ||
| Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo | Q46214428 | ||
| Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease | Q46418067 | ||
| A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. | Q46528728 | ||
| Hydrogen peroxide and peroxynitrite enhance Ca2+ mobilization and aggregation in platelets from type 2 diabetic patients. | Q46553183 | ||
| Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial | Q46627427 | ||
| Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. | Q46678626 | ||
| Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting St | Q46690785 | ||
| Platelet sarcoplasmic endoplasmic reticulum Ca2+-ATPase and mu-calpain activity are altered in type 2 diabetes mellitus and restored by rosiglitazone | Q46856893 | ||
| Prasugrel versus clopidogrel in patients with acute coronary syndromes | Q46915044 | ||
| Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease | Q28222643 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage | Q29616101 | ||
| Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction | Q29618673 | ||
| Ticagrelor versus clopidogrel in patients with acute coronary syndromes | Q29619002 | ||
| A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee | Q29620666 | ||
| Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis | Q33542625 | ||
| Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial | Q34014586 | ||
| Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. | Q34020220 | ||
| 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q34231154 | ||
| Rivaroxaban in patients with a recent acute coronary syndrome | Q34231902 | ||
| Thrombin-receptor antagonist vorapaxar in acute coronary syndromes | Q34231934 | ||
| Vorapaxar in the secondary prevention of atherothrombotic events | Q34263311 | ||
| New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper | Q34267825 | ||
| 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q34318814 | ||
| Platelet dysfunction in type 2 diabetes | Q34319534 | ||
| Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial | Q34404150 | ||
| A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial | Q34751965 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. | Q35540861 | ||
| Advanced glycation endproducts--role in pathology of diabetic complications | Q35994161 | ||
| Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group | Q36244558 | ||
| Atherothrombosis and high-risk plaque: part I: evolving concepts | Q36259704 | ||
| Pathobiology and cell interactions of platelets in diabetes | Q36320564 | ||
| Effects of VLDL and remnant particles on platelets | Q36551304 | ||
| Effects of hyperglycemia and hyperinsulinemia on the tissue factor pathway of blood coagulation | Q36839933 | ||
| Platelet activation and atherothrombosis | Q37031278 | ||
| Oxidative stress and platelets | Q37049876 | ||
| The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. | Q37135995 | ||
| Factors contributing to increased platelet reactivity in people with diabetes | Q37139534 | ||
| Pharmacology of emerging novel platelet inhibitors | Q37227747 | ||
| Diabetes, vascular complications and antiplatelet therapy: open problems. | Q37338975 | ||
| Variability in responsiveness to oral antiplatelet therapy | Q37376462 | ||
| Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions | Q37428365 | ||
| Platelet dysfunction in central obesity | Q37433187 | ||
| Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes | Q46916589 | ||
| Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents | Q46954392 | ||
| A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease | Q50199243 | ||
| Clopidogrel response variability: current status and future directions | Q50329075 | ||
| Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. | Q51079603 | ||
| Determinants of mean platelet volume (MPV) in an elderly population: relevance of body fat, blood glucose and ischaemic electrocardiographic changes. | Q51446902 | ||
| Large Platelets Circulate in an Activated State in Diabetes Mellitus | Q51609166 | ||
| Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. | Q53178855 | ||
| Platelet aggregation in obese and diabetic subjects: association with leptin level. | Q53565307 | ||
| Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) | Q57245141 | ||
| Impacto del tratamiento adyuvante con cilostazol comparado con dosis altas de mantenimiento de clopidogrel en pacientes con diabetes mellitus y respuesta subóptima | Q57764391 | ||
| Functional profile of the platelet P2Y12 receptor signalling pathway in patients with type 2 diabetes mellitus and coronary artery disease | Q57764459 | ||
| Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy | Q57764478 | ||
| Impact of Insulin Receptor Substrate-1 Genotypes on Platelet Reactivity and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease | Q57764490 | ||
| Impact of Diabetes on Long-Term Prognosis in Patients With Unstable Angina and Non–Q-Wave Myocardial Infarction | Q58040699 | ||
| 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction | Q59355957 | ||
| Platelet function in patients with familial hypertriglyceridemia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. | Q60924221 | ||
| Platelet insulin receptor | Q67582366 | ||
| Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity | Q67769877 | ||
| Decreased platelet membrane fluidity due to glycation or acetylation of membrane proteins | Q67956034 | ||
| Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators | Q68021310 | ||
| Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis | Q68053164 | ||
| Altered cellular Ca2+ and Na+ transport in diabetes mellitus | Q68463918 | ||
| Trial of repeated low-dose aspirin in diabetic angiopathy | Q70304992 | ||
| Effects of insulin on calcium metabolism and platelet aggregation | Q71258054 | ||
| Platelets from diabetic subjects show diminished sensitivity to prostacyclin | Q71634275 | ||
| Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria | Q71938783 | ||
| Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia | Q72150727 | ||
| Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitus | Q72595397 | ||
| Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus | Q72786073 | ||
| ADP receptors of platelets and their inhibition | Q74314926 | ||
| Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo | Q74561887 | ||
| Von Willebrand factor in diabetic angiopathy | Q77523254 | ||
| Insulin-induced expression of prostacyclin receptors on platelets is mediated through ADP-ribosylation of Gi alpha protein | Q77636152 | ||
| Alterations of adenine nucleotide metabolism and function of blood platelets in patients with diabetes | Q79678239 | ||
| Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study | Q79685552 | ||
| Membrane lipid fluidity of blood platelets: a common denominator that underlies the opposing actions of various agents that affect platelet activation in whole blood | Q79774080 | ||
| Endogenously generated reactive oxygen species reduce PMCA activity in platelets from patients with non-insulin-dependent diabetes mellitus | Q80158723 | ||
| Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis | Q80550892 | ||
| Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention | Q80611170 | ||
| Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease | Q81607383 | ||
| Effects of intensive glucose control on platelet reactivity in patients with acute coronary syndromes. Results of the CHIPS Study ("Control de Hiperglucemia y Actividad Plaquetaria en Pacientes con Sindrome Coronario Agudo") | Q83541230 | ||
| The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes | Q83797596 | ||
| Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations | Q83927336 | ||
| Cangrelor: a review on its mechanism of action and clinical development. | Q37611039 | ||
| Platelet thrombin receptor antagonism and atherothrombosis | Q37641556 | ||
| Platelet adenosine diphosphate P2Y12 receptor antagonism: benefits and limitations of current treatment strategies and future directions | Q37678656 | ||
| Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist | Q37688144 | ||
| Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis | Q37731651 | ||
| Hyperglycemia: a prothrombotic factor? | Q37759238 | ||
| Aspirin for primary prevention of cardiovascular events in people with diabetes | Q37767786 | ||
| Diabetes and antiplatelet therapy in acute coronary syndrome. | Q37846051 | ||
| Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease | Q38020865 | ||
| Clinical practice. Diagnosis of diabetes | Q38032903 | ||
| Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with c | Q38375360 | ||
| Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux | Q38377760 | ||
| A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOV | Q38470620 | ||
| Pharmacokinetic and pharmacodynamic effects of elinogrel: results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patie | Q38471086 | ||
| Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial | Q38493350 | ||
| Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease | Q38493656 | ||
| Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow | Q39586331 | ||
| Advanced glycation end products, oxidant stress and vascular lesions | Q41375234 | ||
| What cardiologists need to know about diabetes. | Q41556867 | ||
| Insulin, insulin resistance, and platelet signaling in diabetes | Q41951212 | ||
| Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. | Q42453569 | ||
| Alterations in platelet Ca2+ signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production | Q42468613 | ||
| Increased intracellular calcium mobilization in platelets from patients with type 2 (non-insulin-dependent) diabetes mellitus | Q42472895 | ||
| Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Ear | Q42641710 | ||
| Dose Comparisons of Clopidogrel and Aspirin in Acute Coronary Syndromes | Q42917068 | ||
| Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial | Q42917584 | ||
| Elinogrel: pharmacological principles, preclinical and early phase clinical testing | Q42978644 | ||
| Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement | Q43051165 | ||
| Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. | Q43069429 | ||
| Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy | Q43133050 | ||
| Intravenous platelet blockade with cangrelor during PCI. | Q43241907 | ||
| Platelet inhibition with cangrelor in patients undergoing PCI. | Q43241909 | ||
| In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin | Q43260380 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 329-345 | |
| P577 | publication date | 2013-02-13 | |
| P1433 | published in | Journal of Cardiovascular Translational Research | Q6294906 |
| P1476 | title | Platelet function profiles in patients with diabetes mellitus | |
| P478 | volume | 6 |
| Q64935943 | Diabetes and antiplatelet therapy: from bench to bedside. |
| Q89452333 | Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk |
| Q38596700 | Glucose Homeostasis and Cardiovascular Alterations in Diabetes |
| Q35736714 | High-risk type-2 diabetes mellitus patients, without prior ischemic events, have normal blood platelet functionality profiles: a cross-sectional study |
| Q37692590 | Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk |
| Q38378830 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention |
| Q34389439 | Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. |
| Q35766245 | Loss of the insulin receptor in murine megakaryocytes/platelets causes thrombocytosis and alterations in IGF signalling. |
| Q64241217 | Mean Platelet Volume (MPV): New Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions |
| Q46921727 | Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation |
| Q93018504 | Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review |
| Q38846534 | Targeting Select Cellular Stress Pathways to Prevent Hyperglycemia-Related Complications: Shifting the Paradigm |
| Q48512017 | Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets |
Search more.